News - Gilead Sciences, Markets & Marketing

Filter

Popular Filters

Arrival of new hepatitis C therapies will increase the drug-treated population in China

Arrival of new hepatitis C therapies will increase the drug-treated population in China

19-06-2014

China’s market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated…

Anti-viralsasunaprevirBristol-Myers SquibbChinadanoprevirGilead SciencesJanssenMarkets & MarketingOlysioPharmaceuticalRocheSovaldi

Gilead’s Sovaldi set to claim Humira’s crown as top-selling drug in 2020

Gilead’s Sovaldi set to claim Humira’s crown as top-selling drug in 2020

02-05-2014

Having achieved the biggest drug launch to date by generating an astonishing $2.3 billion in its first…

AbbVieAnti-viralsBayerBristol-Myers SquibbCardio-vascularDiabetesGilead SciencesHumiraJanuviaLantusMarkets & MarketingMerck & ConivolumabPharmaceuticalSanofiSovaldiXarelto

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters

17-04-2014

The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

HIV market growth to be impacted by patent expiries

16-04-2014

Due to patent expirations of several key therapies, the human immunodeficiency virus (HIV) treatment…

Anti-viralsapricitabineAtriplaBiotechnologycensavudineelvucitabineGilead SciencesMarkets & MarketingPatentsResearchtenofovir alafenamideTruvadaViread

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

11-04-2014

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

BiotechnologyEuropeGilead SciencesidelalisibImbruvicaJohnson & JohnsonMarkets & MarketingOncologyUSA

Pharmaceutical companies to benefit from new blood cancer drugs

04-04-2014

Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years,…

AmgenCelgeneGilead SciencesJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRoche

Mylan gets exclusive rights to distribute Gilead branded drugs in India

Mylan gets exclusive rights to distribute Gilead branded drugs in India

31-01-2014

US generics major Mylan says its India-based subsidiary has been named) exclusive branded medicines business…

AmbisomeAnti-viralsAsia-PacificBiotechnologyGilead SciencesIndiaMarkets & MarketingMylan LaboratoriesStribildTruvadaViread

Brazil National Health System coverage of and access to HIV drugs

Brazil National Health System coverage of and access to HIV drugs

27-12-2013

Brazil’s National Health System (SUS) currently provides coverage for 22 drugs that are distributed…

AbbVieAnti-viralsAtriplaBrazilEvipleraGilead SciencesGlaxoSmithKlineHealthcareKaletra TabletsMarkets & MarketingPharmaceuticalSouth AmericaTriovirTruvadaViread

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

Actavis confirms generic Exelon Patch patent challenge; InnoPharma debuts generic Vistide in USA

09-03-2013

US generics drugmaker Actavis (NYSE: ACT, formerly trading as Watson) confirmed that it has filed with…

ActavisAnti-viralsExelon PatchGenericsGilead SciencesInnoPharmaMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartisPatentsRegulationVistide

Novartis/Incyte's Jakafi will be greatest growth driver in myelofibrosis market

31-01-2013

Through 2021, the continued uptake of Novartis (NOVN: VX)/Incyte's (Nasdaq: INCY) recently launched JAK-2…

BiotechnologyCYT387EuropeGilead SciencesIncyteJakafiMarkets & MarketingNorth AmericaNovartisOncologyPharmaceuticalYM Biosciences

Patient trust in drugmakers declining, new report shows

14-01-2013

Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients,…

Abbott LaboratoriesBiotechnologyEli LillyGilead SciencesGlaxoSmithKlineGlobalJanssenLundbeckMarkets & MarketingNovartisNovo NordiskPfizerPharmaceuticalPricingResearchRoche

Gilead's Stribild to reinforce HIV/AIDS revenues as key patents expire

06-11-2012

US biotech firm Gilead Science's (Nasdaq: GILD) combination drug Stribild (elvitegravir 150mg/cobicistat…

Anti-viralsAtriplaBiotechnologyBristol-Myers SquibbGilead SciencesMarkets & MarketingPatentsReyatazStribildSustiva

New AHF ad campaign warns preventive use of Gilead AIDS drug Truvada is premature

15-09-2011

The USA-based AIDS Healthcare Foundation (AHF) this week unveiled a new print ad that lays out data on…

Anti-viralsGilead SciencesMarkets & MarketingNorth AmericaPharmaceuticalRegulationTruvada

Back to top